The change in zoster-associated pain treated with oral valaciclovir in immunocompetent patients with acute herpes zoster

Kurokawa, Ichiro; Murakawa, Kazushige; Kumano, K

doi:10.1111/j.1742-1241.2006.01155.x

Cited by 8 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With prevalence of up to 30% and incidence as high as 40–50/1000 PY [276–303], HZ is so common in HIV-infected individuals that it may be a pragmatic prognostic marker [14, 27, 28, 76], especially among younger individuals [304–309]. AIDS patients may have recurrent [73, 76, 77, 80], disseminated [27, 78], or cerebral HZ infections [310, 311].…”

Section: Epidemiology and Risk Factorsmentioning

confidence: 99%

“…Unsurprisingly, many HZ patients have common diseases of older age (Table 4), most frequently hyper-tension, diabetes, malignancies, and pulmonary disorders [11, 12, 15, 23, 26, 28, 137, 154, 166, 339]; however, since comorbidities and/or complications account for high proportion of hospitalised HZ cases [11, 12, 15, 23, 26, 28, 102, 104, 136, 137, 154, 166, 340], these may be more prevalent among such patients than in the general population.…”

Section: Epidemiology and Risk Factorsmentioning

confidence: 99%

“…Definitions of PHN are inconsistent, ranging from ≥1 to ≥6 months since rash onset; however, PHN may persist for years [10]. Reported rates vary widely, depending on patients’ age profiles and the definitions used [20]; nonetheless, the incidence generally ranges between ≤10 to ≥25%, with up to 20% still enduring pain after 6 months (Table 5) [11, 12, 15, 18, 20, 21, 23, 25, 26, 28, 30, 96, 104, 130, 137, 154, 340, 354–359]. PHN correlates strongly with advancing age [15, 18, 21, 96, 102, 137, 340, 356, 357], the other major prognostic factors being the severity of HZ and intensity of acute pain [23, 99, 137, 356, 357, 360–362].…”

Section: Complicating Presentations and Disease Associationsmentioning

confidence: 99%

“…In particular, many patients start therapy too late, the optimal combination of therapies remains uncertain, antiviral agents are underprescribed [22, 645, 771], and even with prompt intervention a substantial proportion remain refractory to treatment; up to 20% of patients with PHN still have persistent neuralgia after 6 months (Table 5) [18–20, 23, 28, 359, 771]. Aciclovir-resistant ocular VZV infections have been encountered [675, 676, 772, 773].…”

Section: Management and Preventionmentioning

confidence: 99%

See 3 more Smart Citations

Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific

et al. 2017

View full text Add to dashboard Cite

BackgroundHerpes zoster (HZ) is a prevalent viral disease that inflicts substantial morbidity and associated healthcare and socioeconomic burdens. Current treatments are not fully effective, especially among the most vulnerable patients. Although widely recommended, vaccination against HZ is not routine; barriers in Asia-Pacific include long-standing neglect of adult immunisation and sparse local data. To address knowledge gaps, raise awareness, and disseminate best practice, we reviewed recent data and guidelines on HZ from the Asia-Pacific region.MethodsWe searched PubMed, Scopus, and World Health Organization databases for articles about HZ published from 1994 to 2014 by authors from Australia, China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, New Zealand, the Philippines, Singapore, Taiwan, Thailand, and Vietnam. We selected articles about epidemiology, burden, complications, comorbidities, management, prevention, and recommendations/guidelines. Internet searches retrieved additional HZ immunisation guidelines.ResultsFrom 4007 retrieved articles, we screened-out 1501 duplicates and excluded 1264 extraneous articles, leaving 1242 unique articles. We found guidelines on adult immunisation from Australia, India, Indonesia, Malaysia, New Zealand, the Philippines, South Korea, and Thailand.HZ epidemiology in Asia-Pacific is similar to elsewhere; incidence rises with age and peaks at around 70 years – lifetime risk is approximately one-third. Average incidence of 3–10/1000 person-years is rising at around 5% per year. The principal risk factors are immunosenescence and immunosuppression. HZ almost always causes pain, and post-herpetic neuralgia is its most common complication. Half or more of hospitalised HZ patients have post-herpetic neuralgia, secondary infections, or inflammatory sequelae that are occasionally fatal. These disease burdens severely diminish patients’ quality of life and incur heavy healthcare utilisation.ConclusionsSeveral countries have abundant data on HZ, but others, especially in South-East Asia, very few. However, Asia-Pacific countries generally lack data on HZ vaccine safety, efficacy and cost-effectiveness. Physicians treating HZ and its complications in Asia-Pacific face familiar challenges but, with a vast aged population, Asia bears a unique and growing burden of disease. Given the strong rationale for prevention, most adult immunisation guidelines include HZ vaccine, yet it remains underused. We urge all stakeholders to give higher priority to adult immunisation in general and HZ in particular.Electronic supplementary materialThe online version of this article (doi:10.1186/s12879-017-2198-y) contains supplementary material, which is available to authorized users.

show abstract

Section: Epidemiology and Risk Factorsmentioning

confidence: 99%

Section: Epidemiology and Risk Factorsmentioning

confidence: 99%

Section: Complicating Presentations and Disease Associationsmentioning

confidence: 99%

Section: Management and Preventionmentioning

confidence: 99%

See 2 more Smart Citations

Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Herpes zoster (HZ) occurs when Varicella zoster virus reactivates from the sensory ganglia during waning of cell‐mediated immunity below a critical level . Over 95% of individuals aged 50 years or older have been infected with Varicella zoster virus and are, therefore, at risk of developing HZ . The lifetime risk of developing HZ is between 25% and 30%, rising to 50% in those who reach 80 years of age .…”

Section: Introductionmentioning

confidence: 99%

Burden of herpes zoster and postherpetic neuralgia in Japanese adults 60 years of age or older: Results from an observational, prospective, physician practice‐based cohort study

Sato

Adachi²,

Nakamura

et al. 2016

The Journal of Dermatology

View full text Add to dashboard Cite

Approximately one in three persons will develop herpes zoster during their lifetime, and it can lead to serious complications such as postherpetic neuralgia. However, evidence on burden of herpes zoster and postherpetic neuralgia in Japan is limited. This prospective, observational, multicenter, physician practice‐based cohort study was conducted in Kushiro, Hokkaido, Japan (Clinicaltrials.gov identifier NCT01873365) to assess the incidence and hospitalization rates of herpes zoster, and the proportion, clinical burden and risk factors for postherpetic neuralgia in adults aged 60 years or more. Within the study area, 800 subjects developed herpes zoster and 412 were eligible for the study. Herpes zoster incidence was 10.2/1000 person‐years and higher among women and older subjects. Subjects with herpes zoster required on average 5.7 outpatient consultations. Herpes zoster‐associated hospitalization rate was 3.4% (27/800). The proportion of postherpetic neuralgia and other complications was 9.2% (38/412) and 26.5% (109/412), respectively. Statistically significant association with the development of postherpetic neuralgia was male sex (odds ratio [OR], 2.51; 95% confidence interval [CI], 1.17–5.38), age of 70–74 years (OR, 3.51; 95% CI, 1.09–11.3), immunosuppressive therapy (OR, 6.44; 95% CI, 1.26–32.9), severe herpes zoster pain at first consultation (OR, 3.08; 95% CI, 1.10–8.62) and rash on upper arms (vs no rash on upper arms; OR, 3.46; 95% CI, 1.10–10.9). Considerable herpes zoster and postherpetic neuralgia burden exists among elderly in Japan, and there may be predictive factors at the first visit which could be indicative of the risk of developing postherpetic neuralgia.

show abstract

Características de los fármacos antivíricos frente a virus del grupo herpes actualización 2009

Tuset¹,

López‐Suñé²,

Cervera

et al. 2010

Enfermedades Infecciosas y Microbiología Clínica

View full text Add to dashboard Cite

The change in zoster-associated pain treated with oral valaciclovir in immunocompetent patients with acute herpes zoster

Cited by 8 publications

References 12 publications

Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific

Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific

Burden of herpes zoster and postherpetic neuralgia in Japanese adults 60 years of age or older: Results from an observational, prospective, physician practice‐based cohort study

Características de los fármacos antivíricos frente a virus del grupo herpes actualización 2009

Contact Info

Product

Resources

About